#$%^&*AU2020239621A120201022.pdf#####ABSTRACT The invention relates to a pharmaceutical formulation comprising a mixture of a non-reducing sugar, a recombinant humanized anti-Her2 monoclonal antibody-MMAE conjugate, and a surfactant. The pharmaceutical formulation has characteristics of reduced particulate matter, reduced aggregates, improved stability of the conjugate, improved appearance of the lyophilized 5 powders and the like.